[go: up one dir, main page]

GB201122139D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201122139D0
GB201122139D0 GBGB1122139.7A GB201122139A GB201122139D0 GB 201122139 D0 GB201122139 D0 GB 201122139D0 GB 201122139 A GB201122139 A GB 201122139A GB 201122139 D0 GB201122139 D0 GB 201122139D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1122139.7A
Other versions
GB2497806A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to GB1122139.7A priority Critical patent/GB2497806A/en
Publication of GB201122139D0 publication Critical patent/GB201122139D0/en
Priority to KR1020147016952A priority patent/KR102011534B1/en
Priority to TW101148629A priority patent/TWI613199B/en
Priority to CN201280070352.3A priority patent/CN104136431B/en
Priority to DK12813423.6T priority patent/DK2794597T3/en
Priority to EP12813423.6A priority patent/EP2794597B1/en
Priority to NO12813423A priority patent/NO2794597T3/no
Priority to PCT/GB2012/053217 priority patent/WO2013093484A1/en
Priority to ES17193874T priority patent/ES2765891T3/en
Priority to HUE12813423A priority patent/HUE036010T2/en
Priority to ES12813423.6T priority patent/ES2655669T3/en
Priority to CA2859604A priority patent/CA2859604C/en
Priority to PT128134236T priority patent/PT2794597T/en
Priority to US14/366,396 priority patent/US9732085B2/en
Priority to NZ626176A priority patent/NZ626176B2/en
Priority to EP17193874.9A priority patent/EP3290413B9/en
Priority to SG11201403402VA priority patent/SG11201403402VA/en
Priority to IN4676CHN2014 priority patent/IN2014CN04676A/en
Priority to MX2014007269A priority patent/MX351471B/en
Priority to JP2014548196A priority patent/JP6137193B2/en
Priority to HK14111900.0A priority patent/HK1198386B/en
Priority to RU2014129797A priority patent/RU2630677C2/en
Priority to PL12813423T priority patent/PL2794597T3/en
Priority to AU2012356374A priority patent/AU2012356374B2/en
Priority to BR112014015669-7A priority patent/BR112014015669B1/en
Publication of GB2497806A publication Critical patent/GB2497806A/en
Priority to PH12014501365A priority patent/PH12014501365A1/en
Priority to IL233154A priority patent/IL233154A/en
Priority to JP2017091408A priority patent/JP6447660B2/en
Priority to US15/644,655 priority patent/US10717738B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1122139.7A 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors Withdrawn GB2497806A (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
BR112014015669-7A BR112014015669B1 (en) 2011-12-21 2012-12-20 COMPOUNDS DERIVED FROM PYRIDINONE AND PYRIMIDINONE, PHARMACEUTICAL COMPOSITION INCLUDING THE SAID COMPOUNDS AND THEIR USE FOR THE TREATMENT OR PREVENTION OF A THROMBOEMBOLIC DISEASE
NZ626176A NZ626176B2 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
EP17193874.9A EP3290413B9 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
CN201280070352.3A CN104136431B (en) 2011-12-21 2012-12-20 Pyridone and pyrimidone derivatives as plasma thromboplastin antecedent a inhibitor
DK12813423.6T DK2794597T3 (en) 2011-12-21 2012-12-20 PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
EP12813423.6A EP2794597B1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
NO12813423A NO2794597T3 (en) 2011-12-21 2012-12-20
PCT/GB2012/053217 WO2013093484A1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
ES17193874T ES2765891T3 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
HUE12813423A HUE036010T2 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
ES12813423.6T ES2655669T3 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as inhibitors of factor XIa
CA2859604A CA2859604C (en) 2011-12-21 2012-12-20 Compounds
PT128134236T PT2794597T (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
US14/366,396 US9732085B2 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor Xia
KR1020147016952A KR102011534B1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
SG11201403402VA SG11201403402VA (en) 2011-12-21 2012-12-20 Compounds
RU2014129797A RU2630677C2 (en) 2011-12-21 2012-12-20 Compounds
AU2012356374A AU2012356374B2 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
MX2014007269A MX351471B (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors.
JP2014548196A JP6137193B2 (en) 2011-12-21 2012-12-20 Novel pyridinone and pyrimidinone derivatives as factor XIa inhibitors
HK14111900.0A HK1198386B (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
TW101148629A TWI613199B (en) 2011-12-21 2012-12-20 Compounds
PL12813423T PL2794597T3 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors
IN4676CHN2014 IN2014CN04676A (en) 2011-12-21 2012-12-20
IL233154A IL233154A (en) 2011-12-21 2014-06-16 Compounds, pharmaceutical compositions comprising the same and uses thereof
PH12014501365A PH12014501365A1 (en) 2011-12-21 2014-06-16 Compounds
JP2017091408A JP6447660B2 (en) 2011-12-21 2017-05-01 Novel pyridinone and pyrimidinone derivatives as factor XIa inhibitors
US15/644,655 US10717738B2 (en) 2011-12-21 2017-07-07 Pyrimidinone and its derivatives inhibiting factor XIa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors

Publications (2)

Publication Number Publication Date
GB201122139D0 true GB201122139D0 (en) 2012-02-01
GB2497806A GB2497806A (en) 2013-06-26

Family

ID=45572893

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1122139.7A Withdrawn GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors

Country Status (1)

Country Link
GB (1) GB2497806A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515938A (en) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 Salt of FXIa inhibitor compound and preparation method and medical application thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (en) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
AU2014300629A1 (en) 2013-06-24 2015-12-24 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN105849109B (en) * 2013-10-30 2018-01-23 拜耳制药股份公司 Substituted oxopyridine derivatives
NO2760821T3 (en) 2014-01-31 2018-03-10
ES2687498T3 (en) 2014-01-31 2018-10-25 Bristol-Myers Squibb Company Macrocycles with heterocyclic P2 ¿groups as inhibitors of factor XIa
ES2714283T3 (en) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrocycles of diamide that are inhibitors of FXIa
EP3197889B1 (en) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2712886T3 (en) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
CA2961981A1 (en) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR102525392B1 (en) * 2014-12-10 2023-04-24 오노 야꾸힝 고교 가부시키가이샤 Dihydroindolizinone derivative
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
CN106632001A (en) * 2016-12-28 2017-05-10 山东诚汇双达药业有限公司 Preparation method of 4-(bromoacetyl) pyridine hydrobromide
KR102500570B1 (en) * 2019-06-28 2023-02-16 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 Tricyclic compounds, their preparation methods and uses
JP7450024B2 (en) * 2019-09-27 2024-03-14 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド FXIa inhibitor and its preparation method and pharmaceutical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4407488A1 (en) * 1994-03-07 1995-09-14 Bayer Ag Use of bi:phenylyl-methyl- or phenyl-pyridyl-methyl- pyridone cpds.
WO2007070826A1 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
WO2008076805A2 (en) * 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515938A (en) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 Salt of FXIa inhibitor compound and preparation method and medical application thereof
CN115515938B (en) * 2020-10-23 2024-05-10 深圳信立泰药业股份有限公司 Salt of FXIa inhibitor compound and preparation method and medical use thereof

Also Published As

Publication number Publication date
GB2497806A (en) 2013-06-26

Similar Documents

Publication Publication Date Title
IL286152A (en) Substituted imidazopyridinyl-aminopyridine compounds
IL233154A0 (en) Compounds
GB201106395D0 (en) Compounds
GB201109763D0 (en) Compounds
ZA201306857B (en) Mesogen-containing compounds
PT2710018T (en) New compounds
GB201118652D0 (en) New compounds
GB201118654D0 (en) New compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
LT2776436T (en) New compounds
GB201107197D0 (en) Compounds
GB201122139D0 (en) Compounds
GB201106814D0 (en) New compounds
EP2717694A4 (en) Novel compounds
EP2771012A4 (en) New compounds
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201118613D0 (en) Compounds
GB201107204D0 (en) Compounds
GB201120805D0 (en) Compounds
GB201109597D0 (en) Compounds
GB201111440D0 (en) Compounds
GB201114195D0 (en) Compounds
GB201115829D0 (en) Compounds

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)